1. Puy H, Gouya L, Deybach JC: Porphyrias. Lancet 375:924, 2010
2. Whatley SD et al: Diagnostic strategies for autosomal dominant acute porphyrias: Retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 55:1, 2009
3. Sassa S, Kappas A: Molecular aspects of the inherited porphyrias. J Intern Med 247:169, 2000
4. Frank J, Christiano AM: The genetic bases of the porphyrias. Skin Pharmacol Appl Skin Physiol 11:297, 1998
5. Whatley SD et al: C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 83:408, 2008
6. Puy H et al: Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria. Am J Hum Genet 60:1373, 1997
7. Ratnaike S, Blake D: The diagnosis and follow-up of porphyria. Pathology 27:142, 1995
8. Thunell S: Porphyrins, porphyrin metabolism and porphyrias. I. Update. Scand J Clin Lab Invest 60:509, 2000
9. Riddle RD, Yamamoto M, Engel JD: Expression of delta-aminolevulinate synthase in avian cells: Separate genes encode erythroid-specific and nonspecific isozymes. Proc Natl Acad Sci U S A 86:792, 1989
10. Yamamoto M et al: An immunochemical study of delta-aminolevulinate synthase and delta-aminolevulinate dehydratase in liver and erythroid cells of rat. Arch Biochem Biophys 245:76, 1986
11. Thunell S, Pomp E, Brun A: Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol 64:668, 2007
12. Crimlisk HL: The little imitator–porphyria: A neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 62:319, 1997
13. Moore MR, Hift RJ: Drugs in the acute porphyrias—toxicogenetic diseases. Cell Mol Biol (Noisy-le-grand) 43:89, 1997
14. Schmidt GA, Corbridge TC: Appendicitis masquerading as acute porphyria. Crit Care Med 19:443, 1991
15. Schuster HP: Abdominal pain in metabolic disorders. Guidelines for patient management for the general surgeon. Zentralbl Chir 113:945, 1988
16. Brezis M et al: Hematin and propranolol in acute intermittent porphyria. Full recovery from quadriplegic coma and respiratory failure. Eur Neurol 18:289, 1979
17. McEneaney D et al: Porphyric neuropathy—A rare and often neglected differential diagnosis of Guillain-Barre syndrome. J Neurol Sci 114:231, 1993
18. Armas R et al: The hepatic porphyrias: Experience with 105 cases. Rev Med Chil 120:259, 1992
19. Groenewald JZ et al: Linkage disequilibrium analysis in a recently founded population: Evaluation of the variegate porphyria founder in South African Afrikaners. Am J Hum Genet 62:1254, 1998
20. Wolff C, Piderit F, Armas-Merino R: Deficiency of porphobilinogen synthase associated with acute crisis. Diagnosis of the first two cases in Chile by laboratory methods. Eur J Clin Chem Clin Biochem 29:313, 1991
21. Sweeney GD: Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. Clin Biochem 19:3, 1986
22. Poh-Fitzpatrick MB: The “priming phenomenon” in the acute phototoxicity of erythropoietic protoporphyria. J Am Acad Dermatol 21:311, 1989
23. Lamola AA et al: Erythropoietic protoporphyria and lead intoxication: The molecular basis for difference in cutaneous photosensitivity. II. Different binding of erythrocyte protoporphyrin to hemoglobin. J Clin Invest 56:1528, 1975
24. Piomelli S et al: Erythropoietic protoporphyria and lead intoxication: The molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro. J Clin Invest 56:1519, 1975
25. Kauppinen R: Porphyrias. Lancet 365:241, 2005
26. Bodaness RS, Chan PC: Singlet oxygen as a mediator in the hematoporphyrin-catalyzed photooxidation of NADPH to NADP+ in deuterium oxide. J Biol Chem 252:8554, 1977
27. Bickers DR, Dixit R, Mukhtar H: Hematoporphyrin photosensitization of epidermal microsomes results in destruction of cytochrome P-450 and in decreased monooxygenase activities and heme content. Biochem Biophys Res Commun 108:1032, 1982
28. Kessel D, Rossi E: Determinants of porphyrin-induced photo-oxidation characterized by fluorescence and absorption spectra. Photochem Photobiol 35:37, 1982
29. Blum HF: Photodynamic Action and Diseases Caused by Light. Princeton, Reinhold, 1941
30. Emiliani C, Delmelle M: The lipid solubility of porphyrins modulates their phototoxicity in membrane models. Photochem Photobiol 37:487, 1983
31. He D, Soter NA, Lim HW: The late phase of hematoporphyrin derivative-induced phototoxicity in mice: Release of histamine and histologic changes. Photochem Photobiol 50:91, 1989
32. Lim HW et al: Delayed phase of hematoporphyrin-induced phototoxicity: Modulation by complement, leukocytes, and antihistamines. J Invest Dermatol 84:114, 1985
33. Schnait FG, Wolff K, Konrad K: Erythropoietic protoprophyria—Submicroscopic events during the acute photosensitivity flare. Br J Dermatol 92:545, 1975
34. Yen A, Gigli I, Barrett KE: Dual effects of protoporphyrin and long wave ultraviolet light on histamine release from rat peritoneal and cutaneous mast cells. J Immunol 144:4327, 1990
35. Sandberg S et al: Porphyrin-induced photodamage to isolated human neutrophils. Photochem Photobiol 34:471, 1981
36. Baart De La Faille H: Experimental protoporphyria in hairless mice. In: Photodermatitis, edited by D Willoughby, J Girouds. Baltimore, University Park Press, 1980, p. 603
37. Varigos G, Schiltz JR, Bickers DR: Uroporphyrin I stimulation of collagen biosynthesis in human skin fibroblasts. A unique dark effect of porphyrin. J Clin Invest 69:129, 1982
38. Latham PS, Bloomer JR: Protoporphyrin-induced photodamage: Studies using cultured skin fibroblasts. Photochem Photobiol 37:553, 1983
39. Wakulchik SD, Schiltz JR, Bickers DR: Photolysis of protoporphyrin-treated human fibroblasts in vitro: Studies on the mechanism. J Lab Clin Med 96:158, 1980
40. Herrmann G et al: Photosensitization of uroporphyrin augments the ultraviolet A-induced synthesis of matrix metalloproteinases in human dermal fibroblasts. J Invest Dermatol 107:398, 1996
41. Lim HW, Gigli I: Role of complement in porphyrin-induced photosensitivity. J Invest Dermatol 76:4, 1981
42. Lim HW et al: Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda. N Engl J Med 304:212, 1981
43. Lim HW, Poh-Fitzpatrick MB, Gigli I: Activation of the complement system in patients with porphyrias after irradiation in vivo. J Clin Invest 74:1961, 1984
44. Vasil KE, Magro CM: Cutaneous vascular deposition of C5b-9 and its role as a diagnostic adjunct in the setting of diabetes mellitus and porphyria cutanea tarda. J Am Acad Dermatol 56:96, 2008
45. Pawliuk R et al: Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase. J Invest Dermatol 124:256, 2005
46. Smith AG, Elder GH: Complex gene-chemical interactions: Hepatic uroporphyria as a paradigm. Chem Res Toxicol 23:712, 2010
47. Sarkany RP: The management of porphyria cutanea tarda. Clin Exp Dermatol 26:225, 2001
48. Brunsting LA: Observations on porphyria cutanea tarda. Arch Dermatol Syphilol 70:551, 1954
49. Brunsting LA, Mason, HL: Porphyria with cutaneous manifestations. Arch Dermatol Syphilol 60:66, 1949
50. Grossman ME et al: Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 67:277, 1979
51. Elder GH, Roberts AG: Uroporphyrinogen decarboxylase. J Bioenerg Biomembr 27:207, 1995
52. Elder GH, Lee GB, Tovey JA: Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N Engl J Med 299:274, 1978
53. Benedetto AV, Kushner JP, Taylor JS: Porphyria cutanea tarda in three generations of a single family. N Engl J Med 298:358, 1978
54. Held JL et al: Erythrocyte uroporphyrinogen decarboxylase activity in porphyria cutanea tarda: A study of 40 consecutive patients. J Invest Dermatol 93:332, 1989
55. Kushner JP, Barbuto AJ, Lee GR: An inherited enzymatic defect in porphyria cutanea tarda: Decreased uroporphyrinogen decarboxylase activity. J Clin Invest 58:1089, 1976
56. Jalil S et al: Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol 8:297, 2010
57. Brady et al: Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 115:868, 2000
58. Phillips JD et al: Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase. Blood 98:3179, 2001
60. Roberts AG et al: Heterogeneity of familial porphyria cutanea tarda. J Med Genet 25:669, 1988
61. Day RS, Eales L, Meissner D: Coexistent variegate porphyria and porphyria cutanea tarda. N Engl J Med 307:36, 1982
62. Sieg I, Bhutani LK, Doss MO: Dual porphyria of coexisting variegata and cutanea tarda. Eur J Clin Chem Clin Biochem 33:405, 1995
63. Watson CJ et al: Porphyria variegata and porphyria cutanea tarda in siblings: Chemical and genetic aspects. Proc Natl Acad Sci U S A 72:5126, 1975
64. Doss MO: New form of dual porphyria: Coexistent acute intermittent porphyria and porphyria cutanea tarda. Eur J Clin Invest 19:20, 1989
65. Shanley BC, Zail SS, Joubert SM: Effect of ethanol on liver delta-aminolaevulinate synthetase activity and urinary porphyrin excretion in symptomatic porphyria. Br J Haematol 17:389, 1969
66. McColl KE et al: Abnormal haem biosynthesis in chronic alcoholics. Eur J Clin Invest 11:461, 1981
67. Hourihane DO, Weir DG: Suppression of erythropoiesis by alcohol. Br Med J 1:86, 1970
68. Kodama T et al: Changes in aminolevulinate synthase and aminolevulinate dehydratase activity in cirrhotic liver. Gastroenterology 84:236, 1983
69. Levere RD: Stilbesterol-induced porphyria: Increased in hepatic delta-aminolevulinic acid synthetase. Blood 28:569, 1966
70. Ochner R, Schmid R: Acquired porphyria in man and rat due to hexachlorobenzene intoxication. Nature 189:499, 1961
71. Cripps DJ, Gocmen A, Peters HA: Porphyria turcica. Twenty years after hexachlorobenzene intoxication. Arch Dermatol 116:46, 1980
72. Courtney KD: Hexachlorobenzene (HCB): A review. Environ Res 20:225, 1979
73. Elder GH, Evans JO, Matlin SA: The effect of the porphyrogenic compound, hexachlorobenzene, on the activity of hepatic uroporphyrinogen decarboxylase in the rat. Clin Sci Mol Med 51:71, 1976
74. Sinclair PR et al: Chlorinated biphenyls induce cytochrome P450IA2 and uroporphyrin accumulation in cultures of mouse hepatocytes. Arch Biochem Biophys 281:225, 1990
75. Elder GH, Sheppard DM: Immunoreactive uroporphyrinogen decarboxylase is unchanged in porphyria caused by TCDD and hexachlorobenzene. Biochem Biophys Res Commun 109:113, 1982
76. Poland A, Glover E: 2,3,7,8-Tetrachlorodibenzo-p-dioxin: A potent inducer of -aminolevulinic acid synthetase. Science 179:476, 1973
77. Smith AG et al: Protection of the Cyp1a2(−/−) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 173:89, 2001
78. Schwetz BA et al: Toxicology of chlorinated dibenzo-p-dioxins. Environ Health Perspect 5:87, 1973
79. Sweeny GD et al: Iron deficiency prevents liver toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Science 204:332, 1979
80. Jones KG, Sweeney GD: Dependence of the porphyrogenic effect of 2,3,7,8-tetrachlorodibenzo(p)dioxin upon inheritance of aryl hydrocarbon hydroxylase responsiveness. Toxicol Appl Pharmacol 53:42, 1980
81. Kushner JP, Steinmuller DP, Lee GR: The role of iron in the pathogenesis of porphyria cutanea tarda. II. Inhibition of uroporphyrinogen decarboxylase. J Clin Invest 56:661, 1975
82. Ajioka JD et al: Down-regulation of hepcidin in porphyria cutanea tarda. Blood 112:4723, 2008
83. Lundvall O: The effect of the replenishment of iron stores after phlebotomy therapy in porphyria cutanea tarda. Acta Med Scand 189:51, 1971
84. de Verneuil H, Sassa S, Kappas A: Purification and properties of uroporphyrinogen decarboxylase from human erythrocytes. A single enzyme catalyzing the four sequential decarboxylations of uroporphyrinogens I and III. J Biol Chem 258:2454, 1983
85. Feldman ES, Bacon BR: Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene-induced porphyria with dietary carbonyl iron overload. Hepatology 9:686, 1989
86. Roberts AG et al: Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 349:321, 1997
87. Roberts AG et al: The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology 25:159, 1997
88. Sampietro M et al: High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 27:181, 1998
89. Bonkovsky HL: Mechanism of iron potentiation of hepatic uroporphyria: Studies in cultured chick embryo liver cells. Hepatology 10:354, 1989
90. Jones KG, Cole FM, Sweeney GD: The role of iron in the toxicity of 2,3,7,8-tetrachlorodibenzo-(p)-dioxin (TCDD). Toxicol Appl Pharmacol 61:74, 1981
91. Kushner JP, Lee GR, Nacht S: The role of iron in the pathogenesis of porphyria cutanea tarda. An in vitro model. J Clin Invest 51:3044, 1972
92. Phillips JD et al: A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci U S A 98:259, 2001
93. Chuang TY, Brashear R, Lewis C: Porphyria cutanea tarda and hepatitis C virus: A case-control study and meta-analysis of the literature. J Am Acad Dermatol 41:31, 1999
94. Lim HW et al: Early-stage HIV infection and hepatitis C virus infection are associated with elevated serum porphyrin levels. J Am Acad Dermatol 39:956, 1998
95. Cam C, Nigogosyan G: Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. JAMA 183:88, 1963
96. Clemmensen O, Thomsen, K: Porphyria cutanea tarda and systemic lupus erythematosus. Arch Dermatol 118:160, 1982
97. Solis JA et al: Association of porphyria cutanea tarda and primary liver cancer: Report of ten cases. J Dermatol 9:131, 1982
98. Poh-Fitzpatrick MB et al: Porphyria cutanea tardia in two patients treated with hemodialysis for chronic renal failure. N Engl J Med 299:292, 1978
99. Elder GH: Porphyrin metabolism in porphyria cutanea tarda. Semin Hematol 14:227, 1977
100. Elder GH, Smith SG, Smyth SJ: Laboratory investigation of the porphyrias. Ann Clin Biochem 27(Pt 5):395, 1990
101. Logan GM et al: Bile porphyrin analysis in the evaluation of variegate porphyria. N Engl J Med 324:1408, 1991
102. Wolff K et al: Microscopic and fine structural aspects of porphyrias. Acta Derm Venereol Suppl (Stockh) 100:17, 1982
103. Epstein JH, Tuffanelli DL, Epstein WL: Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol 107:689, 1973
104. Ippen H: Allgemeinsymptome der spaten Hautporphyrie (Porphyria cutanea tarda) als Hisweise fur deren Behandlung. Dtsch Med Wochenschr 86:127, 1961
105. Lundvall O: Phlebotomy treatment of porphyria cutanea tarda. Acta Derm Venereol Suppl (Stockh) 100:107, 1982
106. Kordac V, Papezova R, Semradova M: Chloroquine in the treatment of porphyria cutanea tarda. N Engl J Med 296:949, 1977
107. Vogler WR, Galambos JT, Olansky S: Biochemical effects of chloroquine therapy in porphyria cutanea tarda. Am J Med 49:316, 1970
108. Swanbeck G, Wennersten G: Treatment of porphyria cutanea tarda with chloroquine and phlebotomy. Br J Dermatol 97:77, 1977
109. Praga M et al: Treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine. N Engl J Med 316:547, 1987
110. Rocchi E et al: Iron removal therapy in porphyria cutanea tarda: Phlebotomy versus slow subcutaneous desferrioxamine infusion. Br J Dermatol 114:621, 1986
111. Stathers GM: Porphyrin-binding effect of cholestyramine. Results of in-vitro and in-vivo studies. Lancet 2:780, 1966
112. Ramsay CA et al: The treatment of porphyria cutanea tarda by venesection. Q J Med 43:1, 1974
113. Mukerji SK, Pimstone NR: Free radical mechanism of oxidation of uroporphyrinogen in the presence of ferrous iron. Arch Biochem Biophys 281:177, 1990
114. Cappellini MD, Pattoneri P: Oral iron chelators. Annu Rev Med 60:25, 2009
115. Saltzer EI, Redeker AG, Wilson JW: Porphyria cutanea tarda. Remission following chloroquine administration without adverse effects. Arch Dermatol 98:496, 1968
116. Taljaard JJ et al: Studies on low dose chloroquine therapy and the action of chloroquine in symptomatic porphyria. Br J Dermatol 87:261, 1972
117. Malina L, Chlumsky J: A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. Acta Derm Venereol 61:346, 1981
118. Malkinson FD, Levitt L: Hydroxychloroquine treatment of porphyria cutanea tarda. Arch Dermatol 116:1147, 1980
119. Scholnick PL, Epstein J, Marver HS: The molecular basis of the action of chloroquine in porphyria cutanea tarda. J Invest Dermatol 61:226, 1973
120. Mustajoki P et al: Heme in the treatment of porphyrias and hematological disorders. Semin Hematol 26:1, 1989
121. Shieh S, Cohen JL, Lim HW: Management of porphyria cutanea tarda in the setting of chronic renal failure: A case report and review. J Am Acad Dermatol 42:645, 2000
122. Toback AC et al: Hepatoerythropoietic porphyria: Clinical, biochemical, and enzymatic studies in a three-generation family lineage. N Engl J Med 316:645, 1987
123. Burry JN, Lawrence JR: Phototoxic blisters from high frusemide dosage. Br J Dermatol 94:495, 1976
124. Ramsay CA, Obreshkova E: Photosensitivity from nalidixic acid. Br J Dermatol 91:523, 1974
125. Epstein JH, Seibert JS: Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization. Arch Dermatol 112:661, 1976
126. Girschich HJ et al: Naproxen-induced pseudoporphyria: Appearance of new skin lesions after discontinuation of treatment. Scand J Rheumatol 24:108, 1995
127. Baer RL: Cutaneous skin changes probably due to pyridoxine abuse. J Am Acad Dermatol 10:527, 1984
128. Riordan CA, Anstey A, Wojnarowska F: Isotretinoin-associated pseudoporphyria. Clin Exp Dermatol 18:69, 1993
129. Lecha M, Puy H, Deybach JC: Erythropoeitic Protoporphyria. Orphanet J Rare Dis 4:19, 2009
130. Wahlin S et al: Erythropoietic protoporphyria in Sweden: Demographic, clinical, biochemical and genetic characteristics. J Intern Med 269:278, 2011
131. Bloomer JR: Characterization of deficient heme synthase activity in protoporphyria with cultured skin fibroblasts. J Clin Invest 65:321, 1980
132. Goerz G et al: Ferrochelatase activities in patients with erythropoietic protoporphyria and their families. Br J Dermatol 134:880, 1996
133. Sassa S et al: Studies in porphyria: Functional evidence for a partial deficiency of ferrochelatase activity in mitogen-stimulated lymphocytes from patients with erythropoietic protoporphyria. J Clin Invest 69:809, 1982
134. Taketani S, Fujita H: The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria. J Bioenerg Biomembr 27:231, 1995
135. Whatley SD et al: Molecular epidemiology of erythropoietic protoporphyria in the U.K. Br J Dermatol 162:642, 2010
136. Gouya L et al: The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 30:27, 2002
137. Romslo I, Gadeholt HG, Hovding G: Erythropoietic protoporphyria terminating in liver failure. Arch Dermatol 118:668, 1982
138. Muley SA et al: Neuropathy in erythropoietic protoporphyrias. Neurology 51:262, 1998
139. Troadec MB: Targeted deletion of the mouse Mitoferrin1 gene: from anemia to protoporphyria. Blood 117:5494, 2011
140. Avner DL, Lee RG, Berenson MM: Protoporphyrin-induced cholestasis in the isolated in situ perfused rat liver. J Clin Invest 67:385, 1981
141. Sarkany RP, Alexander GJ, Cox TM: Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet 344:958, 1994
142. Schneider-Yin X et al: Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet 344:337, 1994
143. Cripps DJ, Scheuer PJ: Hepatobiliary changes in erythropoietic protoporphyria. Arch Pathol 80:500, 1965
144. Lamon JM, Poh-Fitzpatrick MB, Lamola AA: Hepatic protoporphyrin production in human protoporphyria. Effects of intravenous hematin and analysis of erythrocyte protoporphyrin distribution. Gastroenterology 79:115, 1980
145. Scholnick P, Marver HS, Schmid R: Erythropoietic protoporphyria: Evidence for multiple sites of excess protoporphyrin formation. J Clin Invest 50:203, 1971
146. Doss MO, Frank M: Hepatobiliary implications and complications in protoporphyria a 20-year study. Clin Biochem 22:223, 1989
147. Poh-Fitzpatrick MB et al: Rapid quantitative assay for erythrocyte porphyrins. Arch Dermatol 110:225, 1974
148. Poh-Fitzpatrick MB, Lamola AA: Direct spectrofluorometry of diluted erythrocytes and plasma: A rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med 87:362, 1976
149. Peterka ES, Fusaro RM, Goltz RW: Erythropoietic protoporphyria. II. Histological and histochemical studies of cutaneous lesions. Arch Dermatol 92:357, 1965
150. Cripps DJ et al: Four cases of erythropoietic protoporphyria presenting as light-sensitive lipoid proteinosis. Proc R Soc Med 57:1095, 1964
151. Ryan EA, Madill GT: Electron microscopy of the skin in erythropoietic protoporphyria. Br J Dermatol 80:561, 1968
152. Breathnach SM et al: Immunohistochemical studies of amyloid P component and fibronectin in erythropoietic protoporphyria. Br J Dermatol 108:267, 1983
153. Klatskin G, Bloomer JR: Birefringence of hepatic pigment deposits in erythropoietic protoporphyria. Specificity of polarization microscopy in the identification of hepatic protoporphyrin deposits. Gastroenterology 67:294, 1974
154. Wolff K: Liver inclusions in erythropoietic protoporphyria. Eur J Clin Invest 5:21, 1975
155. Mathews-Roth MM et al: Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch Dermatol 113:1229, 1977
156. Minder EI et al: A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 55:84, 2009
157. Corbett MF et al: The long-term treatment with beta-carotene in erythropoietic protoporphyria: A controlled trial. Br J Dermatol 97:655, 1977
158. Wertz K et al: Beta-carotene inhibits UVA-induced matrix metalloprotease 1 and 10 expression in keratinocytes by a singlet oxygen-dependent mechanism. Free Radic Biol Med 37:654, 2004
159. Wertz K et al: beta-Carotene interferes with ultraviolet light A-induced gene expression by multiple pathways. J Invest Dermatol 124:428, 2005
160. Mathews-Roth MM et al: A double-blind study of cysteine photoprotection in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 10:244, 1994
161. Bechtel MA, Bertolone SJ, Hodge SJ: Transfusion therapy in a patient with erythropoietic protoporphyria. Arch Dermatol 117:99, 1981
162. McCullough AJ et al: Fecal protoporphyrin excretion in erythropoietic protoporphyria: Effect of cholestyramine and bile acid feeding. Gastroenterology 94:177, 1988
163. Gordeuk VR et al: Iron therapy for hepatic dysfunction in erythropoietic protoporphyria. Ann Intern Med 105:27, 1986
164. Milligan A et al: Erythropoietic protoporphyria exacerbated by oral iron therapy. Br J Dermatol 119:63, 1988
165. Seth AK et al: Liver transplantation for porphyria: Who, when and how? Liver Transpl 13:1219, 2007
166. Wahlin S et al: Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 46:174, 2007
167. Rand EB et al: Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 118:1896, 2006
168. Pawliuk R et al: Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 5:768, 1999
169. Cernik C, Haller N, Mostow EN: Adult-onset erythropoietic porphyria in the setting of MDS. Arch Dermatol 145:948, 2009
170. Tsai SF, Bishop DF, Desnick RJ: Purification and properties of uroporphyrinogen III synthase from human erythrocytes. J Biol Chem 262:1268, 1987
171. Tsai SF, Bishop DF, Desnick RJ: Human uroporphyrinogen III synthase: Molecular cloning, nucleotide sequence, and expression of a full-length cDNA. Proc Natl Acad Sci U S A 85:7049, 1988
172. Phillips JD et al: Congenital erythropoietic porphyria due to a mutation in GATA-1: The first trans-acting mutation causative for a human porphyria. Blood 109:2618, 2007
173. Fritsch C et al: Congenital erythropoietic porphyria. J Am Acad Dermatol 36:594, 1997
174. Poh-Fitzpatrick MB: Erythropoietic porphyrias: Current mechanistic, diagnostic, and therapeutic considerations. Semin Hematol 14:211, 1977
175. Nordmann Y et al: Coexistent hereditary coproporphyria and congenital erythropoietic porphyria (Gunther disease). J Inherit Metab Dis 13:687, 1990
176. Piomelli S et al: Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. N Engl J Med 314:1029, 1986
177. Pimstone NR, Gandhi SN, Mukerji SK: Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 316:390, 1987
178. Minder EI, Schneider-Yin X, Moll F: Lack of effect of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 330:1092, 1994
179. Shaw PH et al: Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: A case report and review of the literature. Bone Marrow Transplant 27:101, 2001
180. Thomas C et al: Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr 129:453, 1996
181. Waldenström J: Studien Über Porphyrie. Acta Med Scand 92 (Suppl. 82):1, 1937
182. Anderson PM, Desnick RJ: Purification and properties of uroporphyrinogen I synthase from human erythrocytes. Identification of stable enzyme-substrate intermediates. J Biol Chem 255:1993, 1980
183. Chretien S et al: Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci U S A 85:6, 1988
184. Grandchamp B: Acute intermittent porphyria. Semin Liver Dis 18:17, 1998
185. de Matteis F: Disturbances of liver porphyrin metabolism caused by drugs. Pharmacol Rev 19:523, 1967
186. McColl KE, Moore R: The porphyrias: An example of pharmacogenetic disease. Scott Med J 26:32, 1981
187. McDougall AJ, McLeod JG: Autonomic neuropathy, II: Specific peripheral neuropathies. J Neurol Sci 138:1, 1996
188. Hoesch K: Über die Auswertung der Urobilinogenurie und die “umgekehrte” Urobilinogenurie. Dtsch Med Wochenschr 72:704, 1947
189. Thunell S et al: Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scand J Clin Lab Invest 60:541, 2000
190. Elder GH, Hift RJ: Treatment of acute porphyria. Hosp Med 62:422, 2001
191. Mustajoki P, Nordmann Y: Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 153:2004, 1993
192. Anderson KE et al: A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med 150:1469, 1990
193. Handschin Cet al: Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122:505, 2005
194. Dhar GJ et al: Effects of hematin in hepatic porphyria. Further studies. Ann Intern Med 83:20, 1975
195. Goetsch CA, Bissell DM: Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med 315:235, 1986
196. Tenhunen R, Mustajoki P: Acute porphyria: Treatment with heme. Semin Liver Dis 18:53, 1998
197. de Rooij F et al: Six new protoporphyrinogen oxidase mutations in Dutch variegate porphyria patients and the R59W mutation in historical perspective (abstract). Acta Haematol 98:96, 1997
198. Meissner PN et al: A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 13:95, 1996
199. Mustajoki P: Variegate porphyria. Ann Intern Med 89:238, 1978
200. Deybach JC et al: Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. Hum Mol Genet 5:407, 1996
201. Frank J et al: Homozygous variegate porphyria: Missense mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. J Invest Dermatol 108:647, 1997
202. Lam H et al: Molecular basis of variegate porphyria: A de novo insertion mutation in the protoporphyrinogen oxidase gene. Hum Genet 99:126, 1997
203. Taketani S et al: The human protoporphyrinogen oxidase gene (PPOX): Organization and location to chromosome 1. Genomics 29:698, 1995
204. Frank J et al: Identification of a founder mutation in the protoporphyrinogen oxidase gene in variegate porphyria patients from chile. Hum Hered 51:160, 2001
205. Dean G: The Porphyrias. Philadelphia, Lippincott, 1963
206. Hift RJ et al: Homozygous variegate porphyria: An evolving clinical syndrome. Postgrad Med J 69:781, 1993
207. Palmer RA et al: Homozygous variegate porphyria: A compound heterozygote with novel mutations in the protoporphyrinogen oxidase gene. Br J Dermatol 144:866, 2001
208. Rimington C, Lockwood WH, Belcher RV: The excretion of porphyrin-peptide conjugates in porphyria variegata. Clin Sci 35:211, 1968
209. Kushner JP: Laboratory diagnosis of the porphyrias. N Engl J Med 324:1432, 1991
210. Eales L, Dowdle EB: The place of screening tests and quantitative investigations in the diagnosis of the porphyrias, with particular reference to variegate and symptomatic porphyria. S Afr J Lab Clin Med 40:63, 1966
211. Poh-Fitzpatrick MB: A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 116:543, 1980
212. Cramers M, Jepsen LV: Porphyria variegata: Failure of chloroquin treatment. Acta Derm Venereol 60:89, 1980
213. Lamoril J et al: A molecular defect in coproporphyrinogen oxidase gene causing harderoporphyria, a variant form of hereditary coproporphyria. Hum Mol Genet 4:275, 1995
214. Lee DS et al: Structural basis of hereditary coproporphyria. Proc Natl Acad Sci U S A 102:14232, 2005
215. Schmitt C et al: Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria. Hum Mol Genet 14:3089, 2005
216. Fujita H et al: Characterization and expression of cDNA encoding coproporphyrinogen oxidase from a patient with hereditary coproporphyria. Hum Mol Genet 3:1807, 1994
217. Sassa S et al: Molecular defects of the coproporphyrinogen oxidase gene in hereditary coproporphyria. Cell Mol Biol (Noisy-le-grand) 43:59, 1997
218. Grandchamp B, Lamoril J, Puy H: Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyria. J Bioenerg Biomembr 27:215, 1995
219. Moder KG, Schwenk NM: A coproporphyria-like syndrome induced by glipizide. Mayo Clin Proc 66:312, 1991
220. Doss M et al: New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr 57:1123, 1979
221. Gross U et al: 5-Aminolevulinic acid dehydratase deficiency porphyria: A twenty-year clinical and biochemical follow-up. Clin Chem 44:1892, 1998
222. Sassa S: ALAD porphyria. Semin Liver Dis 18:95, 1998
223. Thunell S, Holmberg L, Lundgren J: Aminolaevulinate dehydratase porphyria in infancy. A clinical and biochemical study. J Clin Chem Clin Biochem 25:5, 1987
224. Ben-Ezzer J, Oelsner H, Szeinberg A: Genetic polymorphism of delta-aminolevulinate dehydrase in several population groups in Israel. Hum Hered 37:229, 1987
225. Harraway JR et al: Dual porphyria with mutations in both the UROD and HMBS genes. Ann Clin Biochem 43:80, 2006
226. Akagi R et al: Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. Br J Haematol 132:237, 2006
227. Lim HW et al: Photosensitivity, abnormal porphyrin profile, and sideroblastic anemia. J Am Acad Dermatol 27:287, 1992
228. Rothstein G, Lee R, Cartwright GE: Sideroblastic anemia with dermal photosensitivity and greatly increased erythrocyte protoporphyrin. N Engl J Med 280:587, 1969
229. Sato Y et al: [A case of sideroblastic anemia with dermal photosensitivity and increased erythrocyte protoporphyrin (author's transl)]. Rinsho Ketsueki 22:1971, 1981
230. Fontanellas A et al: Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. Gene Ther 8:618, 2001
231. de Verneuil H, Moreau-Gaudry F, Ged C: [A model of congenital erythropoietic porphyria for gene transfer in hematopoietic cells]. Transfus Clin Biol 4:263, 1997